Panbela Therapeutics shares are trading higher after the company announced that the independent Data Safety Monitoring Board recommended the study continue without modification.
Portfolio Pulse from Benzinga Newsdesk
Panbela Therapeutics' stock is trading higher following a recommendation from the independent Data Safety Monitoring Board to continue its study without modification.

November 29, 2023 | 5:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Panbela Therapeutics' shares are experiencing an uptick after a positive endorsement from the Data Safety Monitoring Board to proceed with its study as planned.
The recommendation from the independent Data Safety Monitoring Board to continue the study without modification is a positive signal for investors, suggesting that the study is proceeding as expected without any safety concerns. This can lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100